These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12804699)

  • 1. Antisense therapeutics: from theory to clinical practice.
    Pirollo KF; Rait A; Sleer LS; Chang EH
    Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense-based cancer therapeutics: are we there yet?
    Rayburn ER; Wang H; Zhang R
    Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
    Chen HX
    Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
    [No Abstract]   [Full Text] [Related]  

  • 9. Antisense therapy: recent advances and relevance to prostate cancer.
    Benimetskaya L; Stein CA
    Clin Prostate Cancer; 2002 Jun; 1(1):20-30. PubMed ID: 15046709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S; Kandimalla ER
    Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
    Uhlmann E
    Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locked nucleic acid holds promise in the treatment of cancer.
    Frieden M; Ørum H
    Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of delivery systems to improve target efficacy of oligonucleotides.
    Shoji Y; Nakashima H
    Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.
    Nakata Y; Kim TK; Shetzline S; Gewirtz AM
    Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides in cutaneous therapy.
    Wraight CJ; White PJ
    Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.
    Coppelli FM; Grandis JR
    Curr Pharm Des; 2005; 11(22):2825-40. PubMed ID: 16101440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
    Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058
    [No Abstract]   [Full Text] [Related]  

  • 20. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.